Xspray Pharma AB (publ) (XSPRAS.XC)
| Previous close | 49.4000 |
| Open | 49.9000 |
| Bid | 48.3000 x N/A |
| Ask | 0.0000 x N/A |
| Day's range | 49.5000 - 49.9000 |
| 52-week range | 49.5000 - 49.9000 |
| Volume | |
| Avg. volume | N/A |
| Market cap | N/A |
| Beta (5Y monthly) | 0.99 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Business WireXspray to present data at ASCO highlighting frequent comedication of PPIs with TKIs in CML-patients and greater than expected negative effects on the bioavailability of crystalline dasatinib
STOCKHOLM, May 23, 2024--Xspray Pharma AB (publ) (Nasdaq Stockholm: XSPRAY), a Swedish pharmaceutical company which uses its innovative Hynap technology to develop 505(b)(2) improved versions of marketed drugs for the treatment of cancer announced today the online publication of its abstract titled "Frequency of Comedication of Proton Pump Inhibitors with Crystalline Dasatinib in Chronic Myeloid Leukemia and Effects on TKI-Bioavailability" for presentation at the upcoming American Society of Cli
Business WireFDA Accepts Xspray Pharma’s NDA-resubmission for Dasynoc® – PDUFA Date set to 31 July 2024
STOCKHOLM, February 12, 2024--Xspray Pharma AB (publ) (Nasdaq Stockholm: XSPRAY): The U.S. Food and Drug Administration (FDA) has accepted the resubmission of Xspray Pharma’s New Drug Application (NDA) for Dasynoc®, following a Complete Response Letter (CRL) where additional information was requested. The FDA has now assigned a Prescription Drug User Fee Act (PDUFA) date to 31st of July, 2024. This is the FDA’s deadline for completing the approval process, marking a significant milestone for Das
Business WireXspray Pharma’s XS003 Achieves Superior Bioavailability Milestone, Matching TASIGNA® at Reduced Dosage
STOCKHOLM, November 21, 2023--Xspray Pharma AB (Stockholm/Nasdaq: XSPRAY) a biotechnology company developing improved PKIs for cancer treatment, through its proprietary HyNap™ technology, today announced that XS003, its amorphous, non-crystalline formulation of nilotinib, has demonstrated bioavailability within the 80-125% range to TASIGNA® following oral administration with significantly lower dose. This is the second of three announced amorphous PKIs under development by Xspray using the HyNap
